Erdos, J. and Sehic, O. and Wild, C. (2021): ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies. AIHTA Policy Brief 001/ 1. Update.

Galician Agency for Health Technology Assessment (avalia-t), EUnetHTA and Regione Emilia Romagna (RER), EUnetHTA (2018): Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA-Report. HTA-Projektbericht 103.

Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.

Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.

Glanz, K.A. (2021): Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with Real World Evidence (RWE). HTA-Projektbericht 140.

Jonas, S. (2004): [Genetic testing. Editorial]. HTA-Newsletter 31: p. 1.

Jonas, S. and Schamberger, C. and Wild, C. (2002): [Predictive genetic diagnosis for breast and colon carcinoma: Diagnosis, treatment, public health aspects]. ITA-Projektbericht 21.

Jonas, S. and Wild, C. and Schamberger, C. (2003): [Predictive genetic testing for breast and colorectal cancer]. ZaeFQ: Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 97 (01): pp. 67-71.

Jonas, S. and Wild, C. and Schamberger, C. (2002): Predictive genetic testing for mammary and colorectal cancer. Wiener Klinische Wochenschrift 114 Suppl. (17-18): p. 24.

Kis, A. and Wild, C. and Bodamer, O. (2008): Enzyme Replacement Therapy for Lysosomal Storage Diseases. Decision Support Document 19.

Mikl, M. and Wild, C. and Torgersen, H. (1995): [Genetic analysis: Practice of diagnosis and counseling in Austria]. ITA-Projektberichte.

Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.

Radlberger, P. (2006): [Predictive genetic diagnostics: Testing for breast cancer]. HTA-Newsletter 52: p. 2.

Sehic, O. and Wild, C. (2022): ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022. AIHTA Policy Brief 006b/ 1. Update.

Walter, M. and Strohmaier, C. (2020): Genetic Testing in the Context of Familial Hypercholesterolaemia Management. HTA-Projektbericht 130.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Wild, C. (2004): [Genetic testing for predisposition]. ITA-Newsletter December 2004: p. 8.

Wild, C. (2004): [Genetic testing for predisposition]. HTA-Newsletter 31: p. 4.

Wild, C. (2002): [Predictive genetic testing for breast and prostate cancer]. HTA-Newsletter 07: p. 2.

Wild, C. (2008): Polymorphism-screening: genetic testing for predisposition - guidance for technology assessment. Poiesis & Praxis: International Journal of Ethics of Science and Technology Assessment 05 (01): pp. 1-14.

Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.

Wild, C. and Jonas, S. (2003): [To what extent can the publicly sponsored health system afford predictive genetic diagnostics? - First approaches to pinpoint and limit responsibilities, exemplified by hereditary carcinomas]. Das Gesundheitswesen 65 (06): pp. 351-358.

Wild, C. and Jonas, S. (2002): [Predictive genetic testing for breast and colon cancer]. Newsletter der Österreichischen Gesellschaft für Public Health (3): p. 1.

Wild, C. and Jonas, S. and Schamberger, C. (2003): Predictive genetic testing for hereditary cancer. Value in Health 6 (6): pp. 794-795.

Wild, C. and Jonas, S. and Schamberger, C. (2002): [Predictive genetic diagnostics for hereditary cancer]. Mitteilungen der Sanitätsverwaltung 01: pp. 6-8.

Wild, C. and Mikl, M. (1996): [Medical genetics in Austria: Opportunities and risks]. Soziale Technik (3): pp. 6-8.

Wild, C. and Mikl, M. (1996): [Medical genetics in Austria]. Journal für Sozialforschung 36 (01): pp. 87-108.

Wohlhöfner, K. (2021): (Good) practice organisational models using real-world evidence for public funding of high prized therapies. HTA-Projektbericht 138.

Zorginstituut Nederland (ZIN), EUnetHTA and Belgian Health Care Knowledge Centre (KCE), EUnetHTA (2018): MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EUnetHTA report . HTA-Projektbericht 102.